[Direct and indirect effects of epoietin alpha in an experimental model of thrombosis and bleeding in the rabbit].
OBJECTIVE
To study direct and indirect effects of EPO on haemostasis.


METHODS
Experimental, randomised.


METHODS
Forty-eight New Zealand rabbits.


METHODS
Animals were anaesthetised, ventilated and monitored continuously for blood pressure, heart rate, body temperature, and carotid blood flow variations and were randomised into four groups: control, EPO bolus 2400 IU kg(-1), fractionated EPO (one injection a week of 600 IU kg(-1) for 4 weeks), homologous red blood cell transfusion to reach the Ht level of the fractionated EPO group. A compression injury and a 75% stenosis of the carotid artery triggered a series of cyclic flow reductions (CFRs). CFRs were observed for a 20 min period in each group. Ear immersion bleeding time (BT) and hepato-splenic bleeding were performed at the end of the experiment. Biology was performed at the end of the thrombosis period: blood cells count, Hte, activated partial thromboplastin time, fibrinogen, arachidonic-induced platelet aggregation, EPO dosages.


RESULTS
No significant increase in thrombosis (CFRs) in the two EPO groups and in the transfused group. Increase in Hte in the fractionated EPO group versus control. Group EPO bolus: decrease in BT and hepato-splenic bleeding versus control; decrease in hepato-splenic bleeding versus fractionated EPO group, increase in platelet aggregation velocity versus control.


CONCLUSIONS
EPO did not increase the thrombotic risk in this rabbit model. EPO bolus decreased BT and hepato-splenic bleeding.
Pham Tourreau
S
S
Laboratoire du groupe de recherche en anesthésie réanimation urgences (GRARU) et Inserm U 348, département d'anesthésie-réanimation, CHU d'Avicenne, université Paris-XIII, France.
Fattorutto
M
M
Bonnin
P
P
Mazoyer
E
E
Raphaël
M
M
Morin
F
F
Cupa
M
M
Samama
C-M
CM
D000818:Animals; D001760:Bleeding Time; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002339:Carotid Arteries / Q000187:drug effects; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D005340:Fibrinogen / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006431:Hemobilia / Q000503:physiopathology; D006470:Hemorrhage / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D011994:Recombinant Proteins; D012039:Regional Blood Flow / Q000502:physiology; D013927:Thrombosis / Q000188:drug therapy*
D011994:Recombinant Proteins; D004921:Erythropoietin; D005340:Fibrinogen